Toxic neuropathies: Chemotherapy induced peripheral neurotoxicity

Paola Alberti; Guido Cavaletti; David R. Cornblath

doi:10.1097/WCO.0000000000000724

Toxic neuropathies: Chemotherapy induced peripheral neurotoxicity

Paola Alberti, Guido Cavaletti, David R. Cornblath

School of Medicine

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Purpose of reviewChemotherapy-induced peripheral neurotoxicity (CIPN) is a common and distressing side-effect of many chemotherapy regimens. Currently, aside from symptomatic treatments for neuropathic pain, there are no treatments to prevent CIPN or treat established CIPN. We discuss recent articles addressing clinimetric issues and treatment of CIPN.Recent findingsThere are important clinimetric issues that need to be addressed so that robust clinical trials in CIPN can be performed. There are new compounds in early development that may treat CIPN, but larger studies are needed.SummaryA multidisciplinary, international approach is needed to unravel CIPN; the Toxic Neuropathy Consortium (TNC) of the Peripheral Nerve Society may be the home for such efforts.

Original language	English (US)
Pages (from-to)	676-683
Number of pages	8
Journal	Current opinion in neurology
Volume	32
Issue number	5
DOIs	https://doi.org/10.1097/WCO.0000000000000724
State	Published - Oct 1 2019

Keywords

chemotherapy-induced peripheral neurotoxicity
clinical trials
clinimetric endpoint
patient-reported outcome measure
toxic neuropathy consortium

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.1097/WCO.0000000000000724

Cite this

@article{6ed1d9a777224c14bd536e7e24495b59,

title = "Toxic neuropathies: Chemotherapy induced peripheral neurotoxicity",

abstract = "Purpose of reviewChemotherapy-induced peripheral neurotoxicity (CIPN) is a common and distressing side-effect of many chemotherapy regimens. Currently, aside from symptomatic treatments for neuropathic pain, there are no treatments to prevent CIPN or treat established CIPN. We discuss recent articles addressing clinimetric issues and treatment of CIPN.Recent findingsThere are important clinimetric issues that need to be addressed so that robust clinical trials in CIPN can be performed. There are new compounds in early development that may treat CIPN, but larger studies are needed.SummaryA multidisciplinary, international approach is needed to unravel CIPN; the Toxic Neuropathy Consortium (TNC) of the Peripheral Nerve Society may be the home for such efforts.",

keywords = "chemotherapy-induced peripheral neurotoxicity, clinical trials, clinimetric endpoint, patient-reported outcome measure, toxic neuropathy consortium",

author = "Paola Alberti and Guido Cavaletti and Cornblath, {David R.}",

note = "Funding Information: G.C. is a recipient of a research grant from Associazione Italiana Ricerca sul Cancro (AIRC IG 2016 Id.18631). Publisher Copyright: {\textcopyright} 2019 Wolters Kluwer Health, Inc. All rights reserved.",

year = "2019",

month = oct,

day = "1",

doi = "10.1097/WCO.0000000000000724",

language = "English (US)",

volume = "32",

pages = "676--683",

journal = "Current opinion in neurology",

issn = "1350-7540",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Toxic neuropathies

T2 - Chemotherapy induced peripheral neurotoxicity

AU - Alberti, Paola

AU - Cavaletti, Guido

AU - Cornblath, David R.

N1 - Funding Information: G.C. is a recipient of a research grant from Associazione Italiana Ricerca sul Cancro (AIRC IG 2016 Id.18631). Publisher Copyright: © 2019 Wolters Kluwer Health, Inc. All rights reserved.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Purpose of reviewChemotherapy-induced peripheral neurotoxicity (CIPN) is a common and distressing side-effect of many chemotherapy regimens. Currently, aside from symptomatic treatments for neuropathic pain, there are no treatments to prevent CIPN or treat established CIPN. We discuss recent articles addressing clinimetric issues and treatment of CIPN.Recent findingsThere are important clinimetric issues that need to be addressed so that robust clinical trials in CIPN can be performed. There are new compounds in early development that may treat CIPN, but larger studies are needed.SummaryA multidisciplinary, international approach is needed to unravel CIPN; the Toxic Neuropathy Consortium (TNC) of the Peripheral Nerve Society may be the home for such efforts.

AB - Purpose of reviewChemotherapy-induced peripheral neurotoxicity (CIPN) is a common and distressing side-effect of many chemotherapy regimens. Currently, aside from symptomatic treatments for neuropathic pain, there are no treatments to prevent CIPN or treat established CIPN. We discuss recent articles addressing clinimetric issues and treatment of CIPN.Recent findingsThere are important clinimetric issues that need to be addressed so that robust clinical trials in CIPN can be performed. There are new compounds in early development that may treat CIPN, but larger studies are needed.SummaryA multidisciplinary, international approach is needed to unravel CIPN; the Toxic Neuropathy Consortium (TNC) of the Peripheral Nerve Society may be the home for such efforts.

KW - chemotherapy-induced peripheral neurotoxicity

KW - clinical trials

KW - clinimetric endpoint

KW - patient-reported outcome measure

KW - toxic neuropathy consortium

UR - http://www.scopus.com/inward/record.url?scp=85071506778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071506778&partnerID=8YFLogxK

U2 - 10.1097/WCO.0000000000000724

DO - 10.1097/WCO.0000000000000724

M3 - Review article

C2 - 31306214

AN - SCOPUS:85071506778

SN - 1350-7540

VL - 32

SP - 676

EP - 683

JO - Current opinion in neurology

JF - Current opinion in neurology

IS - 5

ER -

Toxic neuropathies: Chemotherapy induced peripheral neurotoxicity

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this